Allan Young

Allan H. Young is a psychiatrist and academic whose work spans mood disorders, psychopharmacology and translational clinical research. He has led and contributed to a range of clinical studies and reviews examining rapid-acting antidepressants and psychedelic compounds, with particular emphasis on treatment‑resistant depression, neuroimaging correlates of treatment response, and the safety and tolerability of novel interventions. He has been an investigator on randomized and feasibility trials (including protocols for psilocybin-assisted therapy), phase‑1 studies of intranasal DMT formulations, and secondary analyses comparing esketamine with other pharmacotherapies in treatment‑resistant depression. He has also contributed to syntheses of the evidence base for ketamine and esketamine and to reviews of classical psychedelics such as ayahuasca.